PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcgastBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Gastroenterology
 
BMC Gastroenterol. 2012; 12: 121.
Published online Sep 5, 2012. doi:  10.1186/1471-230X-12-121
PMCID: PMC3482574
Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study
Daniel Keszthelyi,corresponding author1,2 Gwen H Dackus,2 Gwen M Masclee,2 Joanna W Kruimel,2 and Ad AM Masclee2
1Top Institute Food and Nutrition, Wageningen, The Netherlands
2Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands
corresponding authorCorresponding author.
Daniel Keszthelyi: daniel.keszthelyi/at/maastrichtuniversity.nl; Gwen H Dackus: g.dackus/at/student.maastrichtuniversity.nl; Gwen M Masclee: g.masclee/at/erasmusmc.nl; Joanna W Kruimel: j.kruimel/at/mumc.nl; Ad AM Masclee: a.masclee/at/mumc.nl
Received April 3, 2012; Accepted August 30, 2012.
Abstract
Background
Patients with irritable bowel syndrome (IBS) seen by a gastroenterologist often utilize medications that may alter intestinal homeostasis. The question arises whether exposure to these drugs is associated with the development of IBS symptoms. Aim of this study was therefore to assess the use of PPIs and NSAIDs in patients with IBS versus controls.
Methods
Cases of IBS from the last 5 years were reviewed. All patients having had at least one prescription for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the time of initial symptom onset were considered exposed. The control group consisted of individuals randomly selected from the general population.
Results
287 cases of IBS were retrieved for analysis together with 287 age and sex-matched controls. Exposure to PPIs and NSAIDs was significantly higher in IBS patients, whereas no association between ACE inhibitor use and IBS was found. PPIs were not significantly associated when excluding patients with gastrointestinal reflux disease or functional dyspepsia. Exposure to SSRIs was also positively associated with IBS, but only when patients with psychiatric comorbidity were included in the analyses.
Conclusions
Medications that may alter intestinal homeostasis such as NSAIDs and PPIs were more frequently used in IBS patients compared to controls. This association might be relevant for everyday clinical practice, but it is remains to be elucidated whether this association is of etiological nature.
Keywords: Irritable bowel syndrome, Proton pump inhibitors, NSAIDs, Small intestinal bacterial overgrowth, Intestinal permeability
Articles from BMC Gastroenterology are provided here courtesy of
BioMed Central